MedPath

The Accuracy and Feasibility of Continuous Glucose Monitoring in COVID-19 Non-Critically Ill Hospitalized Patients: A Pilot Study

Phase 4
Completed
Conditions
The accuracy and feasibility of real-time continuous glucose monitoring (rt-CGM) in non-ICU hospitalized adult COVID-19 patients who had hyperglycemia requiring insulin therapy during admission.
continuous glucose monitoring, COVID-19, accuracy
Registration Number
TCTR20230426007
Lead Sponsor
Specific League Funds
Brief Summary

Rt CGM use in hospitalized patients with COVID 19 infection demonstrates high accuracy and potentially improves glucose control, reduces the frequency of CBG testing, and preserves medical resources.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
15
Inclusion Criteria

1. Hospitalized patients 18 years old of age or older
2. Positive COVID-19 RT-PCR test
3. Hyperglycemia requiring insulin therapy during admission in non-ICU units 4. Capability to use rt-CGMs and perform self-monitoring of CBG

Exclusion Criteria

1. Coagulopathy (INR over 3)
2. Thrombocytopenia (platelet count less than 20,000/uL)
3. Hypotension (defined as BP less than 90/60 mmHg) or poor tissue perfusion
4. Multiorgan failure
5. Significant edema
6. Current treatment with dual antiplatelet therapy or medications known to interfere with the accuracy of CGMs such as hydroxyurea, intravenous ascorbic acid, paracetamol more than 4 grams in 24 hours

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Accuracy of CGM 7 days MARD
Secondary Outcome Measures
NameTimeMethod
Reduction of point of care blood glucose testing 7 days Times
© Copyright 2025. All Rights Reserved by MedPath